Mark Saaka

TL;DR: Pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival in this rural African setting.

TL;DR: Pneumococcal carriage rates among Gambian villagers are very high, and a pneumococcal conjugate vaccine of restricted valency should reduce the pool of antibiotic-resistant pneumococci.

TL;DR: The PCV-9 studied was immunogenic in a Gambian population where it was also found to be efficacious and previously unpublished data on serotype-specific clinical vaccine efficacy from the main trial is reported.

TL;DR: The differences in antibody responses and pneumococcal carriage between the groups diminished following booster with PPV, implying that administration of one or two doses of PCV7, with a booster dose of PPV might lower the cost of protection against IPD in young children in resource poor countries.

TL;DR: Pneumococcal antibody concentrations in Gambian children were high 34–48 months after a 3-dose primary infant vaccination series of PCV-9 for serotypes other than serotypes 1 and 18C, and were significantly higher than in control children for 3 of the 9 serotypes.